Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease
|
Jan 2018
|
Biology of Blood and Marrow Transportation
|
graft versus host disease (GVHD)
|
Diagnosis of paroxysmal nocturnal hemoglobinuria in peripheral blood and bone marrow with six-color flow cytometry.
|
Feb 2012
|
Biomark Med
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes
|
Oct 2016
|
Biomed Pharmacother
|
myelodysplastic syndromes (MDS)
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
|
Jul 2020
|
Blood
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes
|
Jun 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|
Sep 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
|
Jul 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
May 2020
|
Blood
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
MDS-related mutations in aplastic anemia
|
Oct 2014
|
Blood
|
aplastic anemia
|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
|
Jan 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|